BioSpace News Archive

Revenue from commercial therapies increased 368% over same quarter last year and 39% sequentially

Proteostasis Therapeutics, Inc. announced financial results for the third quarter ended September 30, 2019 and provided a corporate update.

E2112 trial passed final interim OS analysis; trial continues, with final OS analysis expected in 2Q20

NovaBay® Pharmaceuticals, Inc., a biopharmaceutical company focusing on commercializing Avenova® for the domestic eye care market, reports financial results for the three and nine months ended September 30, 2019 and provides a business update.

Cutera, Inc. reported financial results for the third quarter ended September 30, 2019.

Basket trial initiated to study poziotinib in patients with EGFR or HER2 mutation-positive malignant solid tumors in an investigator-led study at The University of Texas MD Anderson Cancer Center

Continued progress in Pompe Disease, DMD and DM1 pipeline programs: AT845 IND submitted and clinical start-up activities underway; AT702 IND on track for first quarter 2020 submission

Equillium, Inc., a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat severe autoimmune and inflammatory disorders, announced that Bruce Steel, Equillium’s president and chief business officer, will present at two upcoming investor conferences in November 2019.

Sientra, Inc., a medical aesthetics company, announced its financial results for the third quarter ended September 30, 2019.

Company in Discussions with Regulatory Agencies on Best Path Forward for the Molgradex Autoimmune Pulmonary Alveolar Proteinosis Program